Convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19: a living systematic review
Background Convalescent plasma and hyperimmune immunoglobulin may reduce mortality in patients with viral respiratory diseases, and are being investigated as potential therapies for coronavirus disease 2019 (COVID‐19). A thorough understanding of the current body of evidence regarding benefits and r...
Hlavní autoři: | Piechotta, V, Iannizzi, C, Chai, KL, Valk, SJ, Kimber, C, Dorando, E, Monsef, I, Wood, EM, Lamikanra, AA, Roberts, DJ, McQuilten, Z, So-Osman, C, Estcourt, LJ, Skoetz, N |
---|---|
Médium: | Journal article |
Jazyk: | English |
Vydáno: |
Cochrane Collaboration
2021
|
Podobné jednotky
-
Hyperimmune immunoglobulin for people with COVID-19
Autor: Kimber, C, a další
Vydáno: (2021) -
Convalescent plasma and hyperimmune immunoglobulin to prevent infection with SARS‐CoV‐2
Autor: Valk, SJ, a další
Vydáno: (2021) -
A systematic review of the safety and efficacy of convalescent plasma or immunoglobulin treatment for people with severe respiratory viral infections due to coronaviruses or influenza
Autor: Kimber, C, a další
Vydáno: (2022) -
The role of convalescent plasma and hyperimmune immunoglobulins in the COVID-19 pandemic, including implications for future preparedness
Autor: So-Osman, C, a další
Vydáno: (2024) -
How should we use convalescent plasma therapies for the management of COVID-19?
Autor: Wood, EM, a další
Vydáno: (2020)